Atlas Trials

A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.

Clinical trial NCT05444933 · COMPLETED

Trial details

NCT number
NCT05444933
Sponsor
Ipsen
Status
COMPLETED
Study type
OBSERVATIONAL
Advanced Renal Cell Carcinoma
Start date
2022-09-16
Primary completion
2023-05-12
Enrollment
252

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.